BAY U6751 hydrate, solid, >=98% (HPLC)

BAY U6751 hydrate, solid, >=98% (HPLC)

Biochem/physiol Actions

BAY W1807, the active metabolite of BAY R3401, inhibits muscle glycogen phosphorylase a and b. In gel-filtered liver extracts, racemic BAY U6751 (containing active BAY W1807) was tested for inhibition of phosphorylase in the glycogenolytic (in which only phosphorylase a is active). In liver extracts, BAY U6751 (0.9-36 µmol/L) inhibited glycogen synthesis by phosphorylase b (notwithstanding the inclusion of AMP), but not by phosphorylase a. Inhibition of phosphorylase-a-catalyzed glycogenolysis was partially relieved by AMP (500 µmol/L). BAY U6751 facilitated phosphorylase-a dephosphorylation. Isolated hepatocytes and perfused livers were tested for BAY R3401-induced changes in phosphorylase-a:b ratios and glycogenolytic output.

Caution

Light sensitive. Store in amber vials.

Features and Benefits

This compound was developed by Bayer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

5, 25 mg in glass bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level InChI key InChI Manufacturer Form Assay Price Quantity
3573276 BAY U6751 hydrate, solid, >=98% (HPLC) white 100 QECLOEJXLYHXNF-UHFFFAOYSA-L 1S/C20H22ClNO6.2Na.H2O/c1-5-22-11(4)14(20(27)28-10(2)3)15(12-8-6-7-9-13(12)21)16(18(23)24)17(22)19(25)26;;;/h6-10,15H,5H2,1-4H3,(H,23,24)(H,25,26);;;1H2/q;2*+1 SIGMA-ALDRICH solid ≥98% (HPLC)
£807.86 (exc VAT) per 25MG
-
+
3573277 BAY U6751 hydrate, solid, >=98% (HPLC) white 100 QECLOEJXLYHXNF-UHFFFAOYSA-L 1S/C20H22ClNO6.2Na.H2O/c1-5-22-11(4)14(20(27)28-10(2)3)15(12-8-6-7-9-13(12)21)16(18(23)24)17(22)19(25)26;;;/h6-10,15H,5H2,1-4H3,(H,23,24)(H,25,26);;;1H2/q;2*+1 SIGMA-ALDRICH solid ≥98% (HPLC)
£288.32 (exc VAT) per 5MG
-
+